Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis

Novo’s attempted rebrand got off to a shaky start this week with the news that the pharma had walked away from a $285 million biobucks pact to develop a monthly weight loss drug after less than two years.